Dengue viral production decreased 1000X if activate Vitamin D Receptor (in lab) – July 2020

Activity of Vitamin D Receptor Agonists Against Dengue Virus

Sci Rep. 2020 Jul 2;10(1):10835. doi: 10.1038/s41598-020-67783-z.
Janejira Jaratsittisin 1, Bin Xu 2, Wannapa Sornjai 1, Zhibing Weng 2, Atichat Kuadkitkan 1, Feng Li 2, Guo-Chun Zhou 3, Duncan R Smith 4

VitaminDWiki

This study tried 7 different Vitamin D Receptors activators in the lab
Tried adding both before or after adding the Dengu virus
Adding activators 1-3 hours after gave the best results


The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019

Vitamin D Receptor activation can be increased by any of: Resveratrol,  Omega-3,  MagnesiumZinc,   Quercetin,   non-daily Vit D,  Curcumin, intense exercise,   Ginger,   Essential oils, etc 
Note: The founder of VitaminDWiki uses 10 of the 12 known VDR activators


Vitamin D fights many viral infections

Many studies have found that VDR activation decreases viral infection

Probably COVID-19 virual infection can also be reduced by VDR activation
Items in both categories Virus and Vitamin D Receptor are listed here:


COVID-19 news
COVID-19 recently updated files
COVID-19 and Vitamin D
COVID-19 and Dark Skins

 Download the PDF from VitaminDWiki
Image
Image
Image
Image
Infections with the mosquito-transmitted dengue virus (DENV) are a pressing public health problem in many parts of the world. The recently released commercial vaccine for DENV has encountered some problems, and there is still no effective drug to treat infections. Vitamin D has a well characterized role in calcium and phosphorus homeostasis, but additionally has a role in the immune response to bacterial and viral pathogens. In this study a number of fused bicyclic derivatives of 1H-pyrrolo1,2imidazol-1-one with vitamin D receptor (VDR) agonist activity were evaluated for possible anti-DENV activity. The results showed that five of the compounds were able to significantly inhibit DENV infection. The most effective compound, ZD-3, had an EC50 value of 7.47 μM and a selective index of 52.75. The compounds were only effective when used as a post-infection treatment and treatment significantly reduced levels of infection, virus output, DENV protein expression and genome copy number. These results suggest that these VDR agonists have the potential for future development as effective anti-DENV agents.

7647 visitors, last modified 04 Jul, 2020,
Printer Friendly Follow this page for updates